Trials / Active Not Recruiting
Active Not RecruitingNCT05404048
PD-L1 PET-imaging During CAR T-cell Therapy
Programmed Death Ligand 1 (PD-L1)-PET Imaging in Patients With (Diffuse) Large B-cell Lymphoma Who Are Treated With CD19-directed CAR T-cell Therapy: a Pilot Study
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- University Medical Center Groningen · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-center, single-arm pilot trial designed to evaluate the expression of PD-L1 in patients with Large B-cell lymphoma (LBCL) and its role in non-responsiveness to chimeric antigen receptor (CAR) T-cell therapy in a non-invasive manner. Moreover, within this trial 89Zr-atezolizumab PET/CT imaging as a tool to distinguish lymphoma activity from a treatment-related inflammatory signal (histiocytic/sarcoid-like reaction) in patients with an end-of-treatment positive FDG PET/CT signal will be evaluated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | 89Zr-atezolizumab PET-imaging | 89Zr-atezolizumab tracer injection + PET/CT-scan |
Timeline
- Start date
- 2022-05-18
- Primary completion
- 2025-12-01
- Completion
- 2026-05-01
- First posted
- 2022-06-03
- Last updated
- 2025-12-03
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT05404048. Inclusion in this directory is not an endorsement.